Reata Pharmaceuticals




MarketCap US

US United States


Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase 2 study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.


Reata Pharmaceuticals was founded in 2002 by Warren Huff and Jack Moss. Within a few years, the company advanced numerous pipeline products into early clinical development, including a novel class of anti-inflammatory drugs known as Nrf2 activators. The company’s lead product candidate, bardoxolone methyl, was licensed to AbbVie in 2012, and it successfully completed several Phase II clinical trials of the NDMA receptor modulator.

Reata Pharmaceuticals’ mission is to develop innovative medicines to treat the root causes of diseases that have the potential to change lives.

Reata’s vision is to provide innovative therapies to patients in need through sustainable and responsible research and development programs.

Key Team

Dr. Colin J. Meyer M.D. (Exec. VP & Chief Innovation Officer)

Ms. Dawn Carter Bir (Exec. VP & Chief Commercial Officer)

Mr. Dakota Gallivan (VP & Chief Healthcare Compliance Officer)

Mr. Steve Harman (Sr. VP & Chief HR Officer)

Mr. Bhaskar Anand (VP & Chief Accounting Officer)

Ms. Elaine Castellanos (Consultant)

Dr. W. Christian Wigley Ph.D. (Sr. VP & Chief Scientific Officer)

Recognition and Awards
Reata’s directors have been recognized with awards from the British Royal Family, the American Society of Hematology, and Ernst & Young, among many others.

Reata Pharmaceuticals
Leadership team

Mr. J. Warren Huff (Chairman & CEO)

Mr. Manmeet Singh Soni (COO, CFO & Pres)

Mr. Michael D. Wortley (Exec. VP & Chief Legal Officer)

Products/ Services
Biopharma, Biotechnology, Pharmaceutical
Number of Employees
100 - 500
Irving, Texas, United States
Company Registration
SEC CIK number: 0001358762
2M - 5M
Traded as
Social Media
Sat Feb 24 2024

businessabc offers a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © businessabc powered by ztudium